Top 10 Companies in the (R)-Acetylthio-2-methylpropanoyl chloride (CAS 74345-73-6) Market (2026): Market Leaders Powering Global Pharmaceutical Innovation

MARKET INSIGHTS

Global (R)-Acetylthio-2-methylpropanoyl chloride (CAS 74345-73-6) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 6.5% during the forecast period.

(R)-Acetylthio-2-methylpropanoyl chloride (CAS 74345-73-6) is a chiral acyl chloride intermediate widely utilized in asymmetric synthesis and pharmaceutical manufacturing. This optically active compound serves as a key building block in the preparation of enantioselective drug molecules, particularly in the synthesis of ACE inhibitors such as captopril and related cardiovascular therapeutics. Its reactive acyl chloride functionality and defined stereochemistry make it indispensable in fine chemical and active pharmaceutical ingredient (API) production processes.

The market is steadily gaining traction, driven by growing demand for chiral intermediates in pharmaceutical synthesis, increasing focus on enantiopure drug development, and expanding research activity in asymmetric catalysis. Furthermore, the rising prevalence of cardiovascular diseases globally continues to sustain demand for captopril‑class compounds, directly supporting consumption of this intermediate. Leading fine chemical manufacturers and API suppliers across North America, Europe, and Asia‑Pacific remain the primary contributors to market activity.

(R)-Acetylthio-2-methylpropanoyl chloride (CAS 74345-73-6) Market – View in Detailed Research Report

---

🔟 1. Capot Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Pharmaceutical Grade (R)-Acetylthio-2‑methylpropanoyl chloride for ACE inhibitor synthesis

Capot Chemical is a leading Chinese fine‑chemical manufacturer with a strong focus on chiral intermediates. Their state‑of‑the‑art asymmetric synthesis facilities enable high‑yield production of the (R) enantiomer, meeting stringent purity requirements for captopril and other cardiovascular APIs.

Sustainability & Growth Initiatives:

• Implementation of greener acylation processes reducing solvent usage by 35%
• Partnerships with contract manufacturers to expand continuous flow synthesis
• Investment in digital tracking for raw material traceability

---

🕘 9. Hairui Fine Chemical Co., Ltd.

Headquarters: Suzhou, China
Key Offering: Custom Synthesis Grade (R)-Acetylthio-2‑methylpropanoyl chloride for specialty APIs

Hairui specializes in high‑purity chiral intermediates and offers rapid scale‑up for R&D projects. Their modular synthesis lines allow flexible batch sizes, catering to both generic and novel drug development.

Sustainability & Growth Initiatives:

• Carbon‑neutral production target by 2030
• Collaboration with global pharma for green chemistry pilot projects
• Adoption of biocatalytic resolution to improve enantiomeric excess

---

🕘 8. Finetech Industry Limited

Headquarters: Shenzhen, China
Key Offering: Pharmaceutical Grade for large‑scale ACE inhibitor production

Finetech’s integrated supply chain ensures consistent supply of high‑purity intermediates, supporting major API manufacturers in Asia‑Pacific.

Sustainability & Growth Initiatives:

• Implementation of waste‑to‑energy recovery from solvent recycling
• Continuous improvement of process safety protocols
• Expansion of production capacity by 15% annually

---

🕘 7. Shanghai Trustin Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Reagent Grade for research and custom synthesis

Trustin provides high‑quality reagents for academic and industrial research, with a focus on reproducible chiral synthesis.

Sustainability & Growth Initiatives:

• ISO 14001 certification for environmental management
• Development of low‑toxicity handling protocols
• Collaboration with universities for process innovation

---

🕘 6. Bide Pharmatech Ltd.

Headquarters: Chengdu, China
Key Offering: Custom Synthesis Grade for specialty APIs

Bide Pharmatech focuses on niche markets, providing tailored solutions for emerging therapeutic classes.

Sustainability & Growth Initiatives:

• Investment in renewable energy for manufacturing plants
• Partnerships with CROs for early‑stage drug development
• Implementation of AI‑driven reaction optimization

---

🕘 5. Beijing Green Guardee Technology Co., Ltd.

Headquarters: Beijing, China
Key Offering: Pharmaceutical Grade for high‑purity API production

Green Guardee emphasizes safety and environmental compliance, offering secure handling of reactive intermediates.

Sustainability & Growth Initiatives:

• Zero‑waste policy in production lines
• Certification for hazardous material management
• Research into biodegradable solvent alternatives

---

🕘 4. Oakwood Products, Inc.

Headquarters: New York, USA
Key Offering: Pharmaceutical Grade for US and European markets

Oakwood offers rapid scaling and international certifications, supporting diversified supply chains for global pharma.

Sustainability & Growth Initiatives:

• Carbon‑neutral production by 2028
• Strategic alliances with ESG‑focused pharma clients
• Investment in continuous flow technologies

---

🕘 3. Enamine LLC

Headquarters: Kyiv, Ukraine
Key Offering: Custom Synthesis Grade for R&D and specialty applications

Enamine provides rapid synthesis and high‑purity intermediates, leveraging its strong R&D capabilities.

Sustainability & Growth Initiatives:

• Energy‑efficient production processes
• Collaboration with European pharma for green chemistry pilots
• Digital twins for process optimization

---

🕘 2. TCI Chemicals

Headquarters: Tokyo, Japan
Key Offering: Reagent Grade for research and custom synthesis

TCI’s high‑quality reagents support academic and industrial research worldwide.

Sustainability & Growth Initiatives:

• ISO 9001 and ISO 14001 certifications
• Investment in green chemistry research
• Partnerships with leading universities for process development

---

🕘 1. PharmaBlock Sciences (Nanjing), Inc.

Headquarters: Nanjing, China
Key Offering: Pharmaceutical Grade for large‑scale ACE inhibitor production

PharmaBlock combines vertical integration and advanced synthesis to deliver high‑purity intermediates to global pharma.

Sustainability & Growth Initiatives:

• Renewable energy usage in manufacturing plants
• Implementation of circular economy practices
• Strategic partnerships with contract manufacturers for scale‑up

---

Download FREE Sample Report: (R)-Acetylthio-2-methylpropanoyl chloride (CAS 74345-73-6) Market – View in Detailed Research Report

Get Full Report: (R)-Acetylthio-2-methylpropanoyl chloride (CAS 74345-73-6) Market – View in Detailed Research Report

---

🌍 Outlook: The Future of (R)-Acetylthio-2-methylpropanoyl chloride Market

The (R)-Acetylthio-2‑methylpropanoyl chloride market is poised for robust growth driven by continued demand for chiral intermediates in cardiovascular therapeutics and emerging antiviral and anticancer agents. Key drivers include:

• Expansion of biosimilar and generic drug markets, increasing demand for high‑purity intermediates.
• Advances in asymmetric catalysis and biocatalysis improving yield and reducing cost.
• Growing emphasis on green chemistry, with manufacturers adopting solvent‑free and renewable‑energy‑powered processes.
• Strategic partnerships between fine‑chemical producers and contract manufacturers to accelerate continuous flow synthesis.
• Regulatory harmonization across regions, facilitating smoother market entry and scale‑up.

🚀 Future Trends

• Digital twins and AI‑optimized reaction pathways promise up to 30% yield improvements.
• AI‑driven process optimization will reduce safety incidents and improve scalability.
• Emerging markets in Latin America and the Middle East are expected to adopt green chemistry practices, creating new supply opportunities.
• Integration of chiral intermediates into peptide therapeutics and antibody conjugates will broaden application scope.
• Enhanced ESG compliance will become a key differentiator among suppliers, driving investment in sustainable infrastructure.